Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles

被引:171
作者
Cabral, H
Nishiyama, N
Okazaki, S
Koyama, H
Kataoka, K
机构
[1] Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Vasc Regenerat, Bunkyo Ku, Tokyo 1138655, Japan
关键词
polymeric micelle; drug delivery system; dicliloro(1,2-diaminocyclohexane)platinum(II); cancer chemotherapy; controlled release;
D O I
10.1016/j.jconrel.2004.08.022
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Block copolymer micelles, containing dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt), the oxaliplatin parent complex, were prepared through polymer-metal complex formation of DACHPt with poly(ethylene glycol)-poly(glutamic acid) block copolymer [PEG-P(Glu)] in distilled water. By dynamic light scattering (DLS) measurement, the micelle size was determined to be 40 run with narrow distribution. The release of platinum complexes from the micelle core was measured in phosphate buffer saline (pH 7.4) at 37 degrees C. DACHPt-loaded micelle showed a sustained release rate of platinum after an induction period of 12 h. In the same conditions, the kinetic stability of DACHPt-loaded micelle, was measured. The micelle was found to be very stable, keeping the initial size, for 240 h. Against murine colon adenocarcinoma 26 (C-26) cells, DACHPt-loaded micelle exhibited considerable in vitro cytotoxicity, lower than oxaliplatin but increasing with exposure time as a result of the release of platinum complexes from the micelle. In vivo biodistribution assay performed on tumor-bearing mice demonstrated that the micelle showed prolonged blood circulation due to its high stability and high tumor accumulation for a prolonged time. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 232
页数:10
相关论文
共 38 条
[1]
Nano-engineering block copolymer aggregates for drug delivery [J].
Allen, C ;
Maysinger, D ;
Eisenberg, A .
COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) :3-27
[2]
CHABNER BA, 1989, CANC PRINCIPLES PRAC
[3]
NEW PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY [J].
CONNORS, TA ;
JONES, M ;
ROSS, WCJ ;
BRADDOCK, PD ;
KHOKHAR, AR ;
TOBE, ML .
CHEMICO-BIOLOGICAL INTERACTIONS, 1972, 5 (06) :415-424
[4]
Cellular and molecular aspects of drugs of the future: oxaliplatin [J].
Di Francesco, AM ;
Ruggiero, A ;
Riccardi, R .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (11) :1914-1927
[5]
PHASE-I STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CANCER [J].
EXTRA, JM ;
ESPIE, M ;
CALVO, F ;
FERME, C ;
MIGNOT, L ;
MARTY, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (04) :299-303
[6]
Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)-malonato-Pt-DACH conjugates [J].
Furin, A ;
Guiotto, A ;
Baccichetti, F ;
Pasut, G ;
Deuschel, C ;
Bertani, R ;
Veronese, FM .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (7-8) :739-749
[7]
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].
Giacchetti, S ;
Perpoint, B ;
Zidani, R ;
Le Bail, N ;
Faggiuolo, R ;
Focan, C ;
Chollet, P ;
Llory, JF ;
Letourneau, Y ;
Coudert, B ;
Bertheaut-Cvitkovic, F ;
Larregain-Fournier, D ;
Le Rol, A ;
Walter, S ;
Adam, R ;
Misset, JL ;
Lévi, F .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147
[8]
Graham MA, 2000, CLIN CANCER RES, V6, P1205
[9]
Enhanced antitumor activitiy of trans(±)-1,2-diaminocyclo-hexaneglutamatoplatinum(II) formulated with stealth liposome [J].
Han, I ;
Kim, OJ ;
Lee, GY ;
Sung, YK ;
Song, R ;
Sohn, YS .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (24) :5443-5447
[10]
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612